Bruker Corp. (BRKR) Dismal Q2 Earnings Weighs On Sentiment

We recently published 10 Big Names Get Slammed. Bruker Corporation (NASDAQ:BRKR) is one of the biggest losers on Monday.

Bruker Corp. dropped its share prices by 12.12 percent on Monday to end at $35.63 apiece following the announcement of disappointing preliminary results for the second quarter of the year.

In a statement, Bruker Corporation (NASDAQ:BRKR) said that revenues during the period were expected to settle at $795 million to $798 million, which suggests a flat performance from the same period last year.

Second quarter 2025 bookings reflected weak academic demand, as well as softness in the US biopharma market.

Non-GAAP earnings per share were also expected to settle between $0.32 and $0.34, representing a $0.19 per share decline year-over-year, including a $0.06 foreign currency headwind.

Following the release, investment firm Stifel maintained its “hold” recommendation for its stock with a price target of $48, or a 34.7-percent upside from its latest closing price.

Bruker Corporation (NASDAQ:BRKR) said official results are scheduled for release before market open on August 4, 2025.

While we acknowledge the potential of BRKR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.